Large pharmaceutical companies cut more than 22,000 jobs in 2025 as a $300 billion patent cliff approaches, signaling a broad industry correction in workforce size and cost structure ahead of significant revenue losses.

These layoffs are not simply cost containment. They reflect deeper strategic recalibration, and companies must respond with greater discipline in portfolio decisions, evidence generation and commercial execution to avoid compounding risk.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.

×